top of page

May 2019 // Company

Synendos Therapeutics was selected among the 10 finalists of the annual >>venture>> competition in health care & nutrition.



Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

October 2022 // Company

Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse Innovation Council. The Innosuisse certificate reflects remark

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c

bottom of page